# Reply to Harsanyi et al. Comment on “Hasan et al. Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma. Clin. Pract. 2023, 13, 806–819”

**Authors:** Abdulkarim Hasan, Yasien Mohammed, Mostafa Basiony, Mehenaz Hanbazazh, Abdulhadi Samman, Mohamed Fayek Abdelaleem, Mohamed Nasr, Hesham Abozeid, Hassan Ismail Mohamed, Mahmoud Faisal, Eslam Mohamed, Diaa Ashmawy, Mohamed Tharwat, Deaa Fekri Morsi, Abeer Said Farag, Eman Mohamed Ahmed, Noha M. Aly, Hala E. Abdel-Hamied, Doaa E. A. Salama, Essam Mandour

PMC · DOI: 10.3390/clinpract16010010 · Clinics and Practice · 2025-12-31

## Full-text entities

- **Genes:** CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** Urothelial Bladder Carcinoma (MESH:D001749)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12839613/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12839613/full.md

---
Source: https://tomesphere.com/paper/PMC12839613